BRCA mutations and their influence on pathological complete response and prognosis in a clinical cohort of neoadjuvantly treated breast cancer patients

[1]  M M Regan,et al.  De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  N. Harbeck,et al.  Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results , 2018, Journal of the National Cancer Institute.

[3]  J. Lubiński,et al.  Predictors of survival for breast cancer patients with a BRCA1 mutation , 2018, Breast Cancer Research and Treatment.

[4]  P. Fasching,et al.  Abstract GS3-05: Survival analysis of the prospectively randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy with weekly nab-paclitaxel with solvent-based paclitaxel followed by anthracycline/cyclophosphamide for patients with early breast cancer – GBG69 , 2018 .

[5]  David Evans,et al.  Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study , 2018, The Lancet. Oncology.

[6]  M. Lux,et al.  Update Breast Cancer 2017 – Implementation of Novel Therapies , 2017, Geburtshilfe und Frauenheilkunde.

[7]  P. Fasching,et al.  Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial , 2017, JAMA oncology.

[8]  M. Rezai,et al.  Abstract P1-09-02: Homologous repair deficiency (HRD) as measure to predict the effect of carboplatin on survival in the neoadjuvant phase II trial GeparSixto in triple-negative early breast cancer , 2017 .

[9]  M. Lux,et al.  Mammographic density is the main correlate of tumors detected on ultrasound but not on mammography , 2016, International journal of cancer.

[10]  P. Fasching,et al.  A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel / carboplatin followed by epirubicin / cyclophosphamide as neoadjuvant chemotherapy in patients with HER2-negative early breast cancer and homologous recombination deficiency (HRD): GeparOLA. , 2016 .

[11]  M. Papa,et al.  Neo-adjuvant doxorubicin and cyclophosphamide followed by paclitaxel in triple-negative breast cancer among BRCA1 mutation carriers and non-carriers , 2016, Breast Cancer Research and Treatment.

[12]  M. Rezai,et al.  Abstract S5-06: BRCA mutations, therapy response and prognosis in the neoadjuvant GeparQuinto study , 2016 .

[13]  M. Rezai,et al.  Abstract S2-04: Early survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto) , 2016 .

[14]  K. Heusinger,et al.  Endometriosis as a risk factor for ovarian or endometrial cancer — results of a hospital-based case–control study , 2015, BMC Cancer.

[15]  F. V. van Leeuwen,et al.  Worse Breast Cancer Prognosis of BRCA1/BRCA2 Mutation Carriers: What's the Evidence? A Systematic Review with Meta-Analysis , 2015, PloS one.

[16]  Alexander Gutin,et al.  Association of BRCA1/2defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes , 2014, Breast Cancer Research.

[17]  Wei-Ting Hwang,et al.  Effects of BRCA1- and BRCA2-Related Mutations on Ovarian and Breast Cancer Survival: A Meta-analysis , 2014, Clinical Cancer Research.

[18]  R. Schulz-Wendtland,et al.  Pooled analysis of the prognostic relevance of progesterone receptor status in five German cohort studies , 2014, Breast Cancer Research and Treatment.

[19]  J. Lubiński,et al.  Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients , 2014, Breast Cancer Research and Treatment.

[20]  Gideon Blumenthal,et al.  Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis , 2014, The Lancet.

[21]  M. Rezai,et al.  Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. , 2014, The Lancet. Oncology.

[22]  M. Rezai,et al.  Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple-negative breast cancer (TNBC): Results from GeparSixto. , 2014 .

[23]  Heng Li,et al.  Toward better understanding of artifacts in variant calling from high-coverage samples , 2014, Bioinform..

[24]  William J. Gradishar,et al.  Response-Guided Neoadjuvant Chemotherapy for Breast Cancer , 2013 .

[25]  J. Lubiński,et al.  Ten-year survival in patients with BRCA1-negative and BRCA1-positive breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  P. Fasching,et al.  Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Peter A Fasching,et al.  Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment , 2011, BMC Cancer.

[28]  Funda Meric-Bernstam,et al.  Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  M. Bani,et al.  Quality Assured Health Care in Certified Breast Centers and Improvement of the Prognosis of Breast Cancer Patients , 2011, Oncology Research and Treatment.

[30]  Nina Ditsch,et al.  Hereditary breast and ovarian cancer: new genes, new treatments, new concepts. , 2011, Deutsches Arzteblatt international.

[31]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  M. Federico,et al.  Favourable ten-year overall survival in a Caucasian population with high probability of hereditary breast cancer , 2010, BMC Cancer.

[33]  Z. Szallasi,et al.  Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  J. Lubiński,et al.  Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  R. Gelber,et al.  Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009 , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  J. Kładny,et al.  Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients , 2009, Breast Cancer Research and Treatment.

[37]  Ofra Barnett-Griness,et al.  Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. , 2007, The New England journal of medicine.

[38]  S. Powell,et al.  The Role of the BRCA1 Tumor Suppressor in DNA Double-Strand Break Repair , 2005, Molecular Cancer Research.

[39]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[40]  Csilla Szabo,et al.  The Breast Cancer Information Core: Database design, structure, and scope , 2000, Human mutation.

[41]  M. Beckmann,et al.  Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. , 2018, The Lancet. Oncology.

[42]  D. Berry,et al.  Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  B. Carter.  Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) , 2013 .

[44]  John L Hopper,et al.  Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.